[Zag Bio^™, Inc.] Zag Bio^™, Inc. announced it has advanced its lead program for type 1 diabetes, ZAG-101, into clinical development. The company’s first-in-human Phase Ib/IIa clinical trial will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ZAG-101 and explore its potential to preserve insulin-producing beta-cell function.

[LRA] The Lupus Research Alliance (LRA), announced the 2026 Global Team Science Award to Dr. Ioannis Parodis and his team of international multidisciplinary experts. The team will use the grant to develop predictive tools that help identify which treatments are most likely to work for people living with lupus, forecast disease progression, and detect early signs of flares.

[Cancer Immunology Research] Researchers showed that T cell immunoglobulin and mucin 3 (Tim-3) expression on tumor Tregs is required for the function and survival of these cells, in part through Akt and FOXO1 signaling.

[Signal Transduction and Targeted Therapy] The authors integrated single-cell transcriptomics and functional assays to identify a distinct CD177⁺ Treg subset that is markedly enriched in metastatic lesions of colorectal liver metastasis patients.

[Nature] Scientists explored how the T cell network is remodelled during non-small cell lung cancer development via multi-omic, cross-tissue immune profiling in patients with preinvasive lung lesions.

[Experimental & Molecular Medicine] The authors shift the focus from static T cell subsets to their dynamic phenotypic flexibility, highlighting how maladaptive transitions drive chronic tissue destruction.

[Alzheimers & Dementia] Scientists investigated the role of Z-DNA-binding protein 1 (ZBP1) in Treg dysfunction under metabolic stress and examined how this interaction influences glial activation, neuronal injury, and cognitive impairment progression.

[Journal of Experimental Medicine] The deletion of the transcription factor Helios in Tregs in mice leads to systemic Th1 immune activation, decreased T follicular regulatory cells, and enhanced germinal center formation. Scientists reported here these mice also exhibited acquired lipodystrophy, hepatic steatosis, and insulin resistance.

[Nature Communications] Investigators reported that expression of the chromatin-organizer protein special AT-rich sequence binding protein 1 (Satb1), in Tregs is critical for their tumor-promoting functions in the tumor microenvironment, but not strictly required to suppress inflammatory T cells in autoimmune colitis.

[Gut] Scientists highlight heterogeneity in Treg abundance, phenotype and function across disease subtypes, stages and tissue compartments, while examining the influence of the local immune microenvironment and gut-liver axis on Treg stability and function.

[Mirum Pharmaceuticals, Inc.] Mirum Pharmaceuticals, Inc. announced the primary endpoint was met in the Phase III portion of the AZURE-1 study evaluating brelovitug, an investigational fully human monoclonal antibody that binds to hepatitis B surface antigen, for the treatment of chronic hepatitis delta virus.

[Genezen] Genezen and InterAct Therapeutics announced a strategic manufacturing partnership to advance the clinical development of a therapy for breast cancer liver metastases, targeting hepatocytes to modulate the liver microenvironment and suppress metastatic outgrowth.